☆ 4.5 Article

Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study

HUMAN VACCINES & IMMUNOTHERAPEUTICS (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Virology

Safety and immunogenicity of inactivated COVID-19 vaccine in health care workers

Saovanee Benjamanukul et al.

Summary: The study investigated the safety and immunogenicity of CoronaVac in the Thai population, showing that a 0-21 days, 2-dose regimen was safe and effective, inducing satisfactory antibody responses. However, antibody levels rapidly declined after 3 months. Recommend 2-dose CoronaVac administration with possible booster doses.

JOURNAL OF MEDICAL VIROLOGY (2022)

添加到收藏夹

Article Immunology

Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults

Ritthideach Yorsaeng et al.

Summary: The immune response after the AZD1222 booster in individuals who received the two-dose CoronaVac vaccine was found to be limited, with lower neutralizing activity against the wild type and variants. However, the AZD1222 booster significantly enhanced the immune response, resulting in higher antibody levels and neutralizing activity.

VACCINE (2022)

添加到收藏夹

Article Immunology

Safety and Immunogenicity of an Inactivated Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine in a Subgroup of Healthy Adults in Chile

Susan M. Bueno et al.

Summary: Vaccination with CoronaVac in Chilean adults aged >= 18 years is safe and induces immune responses, including antibody production and T cell activation. The vaccine demonstrates the generation of neutralizing antibodies and T cell responses in both the 18-59 and >= 60 age groups.

CLINICAL INFECTIOUS DISEASES (2022)

添加到收藏夹

Letter Immunology

Heterologous ChAdOx1-S/BNT162b2 Vaccination: Neutralizing Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Chloe Dimeglio et al.

CLINICAL INFECTIOUS DISEASES (2022)

添加到收藏夹

Article Virology

Evolutionary dynamics of SARS-CoV-2 nucleocapsid protein and its consequences

M. Shaminur Rahman et al.

Summary: The study characterized mutations in the nucleocapsid (N) protein of SARS-CoV-2, identifying a significant number of nucleotide and amino acid mutations. Particularly noteworthy were mutations at primer binding sites and high-frequency mutations impacting the protein's structure.

JOURNAL OF MEDICAL VIROLOGY (2021)

添加到收藏夹

Article Cell Biology

IgA dominates the early neutralizing antibody response to SARS-CoV-2

Delphine Sterlin et al.

Summary: The study found that humoral immune responses to SARS-CoV-2 infection are dominated by IgA antibodies, with specific IgA plasmablasts rapidly expanding shortly after symptom onset and peaking in the third week of the disease. Virus-specific antibody responses include IgG, IgM, and IgA, with IgA playing a greater role in virus neutralization compared to IgG.

SCIENCE TRANSLATIONAL MEDICINE (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection

Shuo Feng et al.

Summary: Defined levels of SARS-CoV-2-specific binding and neutralizing antibodies elicited by the COVID-19 vaccine were identified as correlates of protection against symptomatic infection. Higher levels of immune markers were correlated with a reduced risk of symptomatic infection. The data can be used to extrapolate efficacy estimates to new populations.

NATURE MEDICINE (2021)

添加到收藏夹

Article Immunology

Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection

Jianmin Zuo et al.

Summary: The study shows that functional SARS-CoV-2-specific T cell responses are retained and robust at 6 months following infection, with higher T cell responses observed in donors who had experienced symptomatic infection. Levels of nucleoprotein-specific T cells were correlated with nucleoprotein-specific antibody levels, providing insights into the persistence and correlation of immune responses.

NATURE IMMUNOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data

Robert H Shaw et al.

LANCET (2021)

添加到收藏夹

Editorial Material Immunology

Neutralization of the SARS-CoV-2 Delta variant after heterologous and homologous BNT162b2 or ChAdOx1 nCoV-19 vaccination

Swantje I. Hammerschmidt et al.

CELLULAR & MOLECULAR IMMUNOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial

Xinxue Liu et al.

Summary: Heterologous prime-boost COVID-19 vaccine schedules could facilitate mass immunisation, with ChAd/BNT showing non-inferior immunogenicity compared to ChAd/ChAd, but BNT/ChAd did not demonstrate non-inferiority to BNT/BNT. The results support flexibility in using heterologous prime-boost vaccination with ChAd and BNT COVID-19 vaccines.

LANCET (2021)

添加到收藏夹

Article Medicine, General & Internal

Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial

Alberto M. Borobia et al.

Summary: To date, there are no immunological data on COVID-19 heterologous vaccination schedules in humans. This study evaluated the immunogenicity and reactogenicity of administering BNT162b2 as a second dose in individuals primed with ChAdOx1-S. The results showed that BNT162b2 induced a robust immune response in individuals prime vaccinated with ChAdOx1-S, with an acceptable and manageable reactogenicity profile.

LANCET (2021)

添加到收藏夹

Article Medicine, General & Internal

Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey

Mine Durusu Tanriover et al.

Summary: The study presented the interim efficacy and safety results of the CoronaVac vaccine in a phase 3 clinical trial in Turkey, demonstrating high efficacy against PCR-confirmed symptomatic COVID-19 with good safety and tolerability profile. Results showed significant differences in the frequency of any adverse events between the vaccine and placebo groups, indicating excellent protective effects of the vaccine.

LANCET (2021)

添加到收藏夹

Article Oncology

COVID-19 vaccination and IgG and IgA antibody dynamics in healthcare workers

Sabina Zurac et al.

Summary: The study analyzed IgG and IgA levels in healthcare workers exposed to COVID-19 patients before and after vaccination, showing similar increases in levels regardless of prior infection. Seroconversion was achieved in all subjects following the second round of vaccination.

MOLECULAR MEDICINE REPORTS (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination

Tina Schmidt et al.

Summary: In healthy adults, vaccination with an mRNA vaccine as a booster, regardless of the initial vaccine, resulted in higher levels of spike-specific antibodies and T cells compared to booster vaccination with ChAdOx1 nCov-19. Heterologous vaccination with ChAdOx1 nCoV-19 followed by an mRNA vaccine induced strong immune responses with acceptable reactogenicity, showing similar or better effects than homologous mRNA vaccine regimens.

NATURE MEDICINE (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination

Joana Barros-Martins et al.

Summary: A study found that booster vaccination with BNT162b2 in healthcare professionals previously vaccinated with ChAdOx-1 nCoV-19 elicited more neutralizing antibodies and higher frequencies of virus-specific T cells. Additionally, BNT162b2 induced high titers of neutralizing antibodies against variants of concern, such as B.1.1.7, B.1.351, and P.1.

NATURE MEDICINE (2021)

添加到收藏夹

Letter Medicine, General & Internal

Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination

Johan Normark et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates

Kizzmekia S. Corbett et al.

Summary: In nonhuman primates (NHPs), vaccination with mRNA-1273 induces dose-dependent antibody responses, leading to a significant reduction in viral replication post SARS-CoV-2 challenge. Replication of the virus correlates strongly with antibody levels and neutralizing activity, with lower levels required in the lower airway than in the upper airway. Passive transfer of mRNA-1273-induced IgG is sufficient to provide protection, indicating that humoral immune responses induced by mRNA-1273 vaccine are effective against SARS-CoV-2 in NHPs.

SCIENCE (2021)

添加到收藏夹

Article Immunology

A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: An interim analysis in Indonesia

Eddy Fadlyana et al.

Summary: The study assessed the efficacy, safety, and immunogenicity of an inactivated SARS-CoV-2 vaccine. The interim analysis showed a 65.30% efficacy in preventing COVID-19 illness, with favorable safety and immunogenicity profiles.

VACCINE (2021)

添加到收藏夹

Article Critical Care Medicine

Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study

David Hillus et al.

Summary: This study evaluated the reactogenicity and immunogenicity of homologous and heterologous COVID-19 vaccinations, with results showing that heterologous immunization has good immunogenicity and tolerability.

LANCET RESPIRATORY MEDICINE (2021)

添加到收藏夹

Article Infectious Diseases

Preliminary Evaluation of QuantiFERON SARS-CoV-2 and QIAreach Anti-SARS-CoV-2 Total Test in Recently Vaccinated Individuals

Soumya Jaganathan et al.

Summary: This study evaluated total antibody and T cell responses in COVID-19 convalescents and vaccinated individuals, finding robust immune responses to SARS-CoV-2 mRNA vaccines in vaccinated subjects and sustained responses in convalescent donors for up to 1 year post-infection.

INFECTIOUS DISEASES AND THERAPY (2021)

添加到收藏夹

Letter Immunology

Limited and Short-Lasting Virus Neutralizing Titers Induced by Inactivated SARS-CoV-2 Vaccine

Taweewun Hunsawong et al.

Summary: In vitro testing of serum samples from CoronaVac vaccine recipients showed that neutralizing antibodies provided short-term protection against the original virus strain and limited protection against variants of concern. These findings support the use of vaccine boosters, particularly in regions where variants of concern are circulating.

EMERGING INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Development of an inactivated vaccine candidate for SARS-CoV-2

Qiang Gao et al.

SCIENCE (2020)

添加到收藏夹

Article Medicine, General & Internal

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial

Feng-Cai Zhu et al.

LANCET (2020)

添加到收藏夹

Article Multidisciplinary Sciences

COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses

Ugur Sahin et al.

NATURE (2020)

添加到收藏夹

Article Immunology

Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-infection

Oi-Wing Ng et al.

VACCINE (2016)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.